BioXcel Therapeutics, Inc. (BTAI): Nasdaq/NYSE listing notice — BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal

BioXcel Therapeutics, Inc.

Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.
Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.
Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.
Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.
No assurance that Company will ultimately regain compliance and remain listed on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioXcel Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company’s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to make timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay any further action by the Staff pending the ultimate outcome of the hearing. The Company’s common sto

View on SEC.gov

Browse all listing & compliance notices →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-026708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.